+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Synthetic Biology: Protein Design and Engineering Market by Type of Protein Engineering Approach Used, Type of Protein, Type of Application, Type of End User and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 242 Pages
  • January 2022
  • Region: Global
  • Roots Analysis
  • ID: 5557568
Over the past few years, protein-based therapeutics, including peptides, hormones, vaccines, monoclonal antibodies, blood factors and therapeutic enzymes, have gained a lot of attention from clinical researchers engaged in the field of drug development. The success of these therapeutics can be attributed to the various clinical benefits offered by such products, such as high target specificity, low toxicity and favorable safety profiles. It is worth mentioning that, at present, the protein / peptide therapeutic pipeline features over 345 product candidates, which are being evaluated across more than 1,500 clinical trials worldwide. Further, over 55 such therapies have already been marketed to treat multiple therapeutic indications. However, developing a protein based therapeutic is often fraught with several challenges, such as short half-life and poor chemical and physical stability. To overcome the aforementioned challenges as well as enable the development of therapeutic proteins with improved characteristics, researchers have identified various protein design and engineering techniques. Engineering a protein is a complex multistep process which requires high-throughput techniques and screening procedures. Additionally, it is a time and cost intensive process. Therefore, innovators in the pharmaceutical industry are constantly identifying / developing ways to improve the process of protein engineering. 

Amidst other alternatives, outsourcing protein design and engineering process to a specialized service provider, having the required capability, has emerged as a viable option for various protein / peptide therapeutic developers. Presently, over 85 protein design / protein engineering service providers, along with technology providers, are actively supporting the development of novel protein / peptide therapeutics. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity related to protein design and engineering. Additionally, over 550 patents related to protein design and engineering techniques have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. Driven by the growing demand for therapeutic proteins for personalized medicine and advancement in protein engineering tools, this market is anticipated to witness steady growth in the coming years.


Scope of the Report



The “Protein Design and Engineering Market by Type of Protein Engineering Approach Used (Rational Designing, Directed Evolution and Semi-Rational Designing), Type of Protein (Antibodies, Peptides, Enzymes, Vaccines and Others), Type of Application (Therapeutics and Diagnostics), Type of End User (Pharma / Biotech Firms, CROs and Research / Academic Institutes) and Key Geographies (North America, Europe, APAC, Latin America, MENA and Rest of the World)): Industry Trends and Global Forecasts, 2021-2035” report features an extensive study of the current market landscape and future potential of the protein design and engineering services and technology providers. The study features an in-depth analysis, highlighting the capabilities of protein design and engineering services and technology providers engaged in this domain.


Amongst other elements, the report features:


  • A detailed review of the overall landscape of companies offering protein design and engineering services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with analysis based on various relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to protein design and engineering service(s) offered (protein sequencing, protein library generation, protein screening, protein characterization, protein purification, de-novo protein synthesis and in-silico analysis), additional services offered (protein expression, drug discovery, protein-protein interaction analysis, protein identification, bio imaging of proteins, protein extraction and biological pathway identification), type of protein engineering approach used (directed evolution, rational designing and semi- rational designing), type of protein (antibodies, enzymes, peptides, vaccines and others), type of application (therapeutics and diagnostics) and type of protein expression (cell surface and cell free). 
  • A competitiveness analysis of protein design and engineering service providers, segmented into three categories, namely small (1-50 employees), mid-sized (51-500 employees), and large companies (>500 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and company competitiveness (based on parameters, such as number of protein design and engineering services offered, type of technique used, type of protein engineering approach used, number of additional services offered, application areas and type of protein expression).
  • Elaborate profiles of key players that are engaged in offering services for protein design and engineering. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on services offered, recent developments and an informed future outlook.
  • A detailed assessment of the current market landscape of protein design and engineering technology providers, featuring analysis based on several parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various protein design and engineering technologies based on type of protein design and engineering service(s) supported (protein sequencing, protein library generation, protein screening, protein characterization, de novo protein synthesis and in-silico analysis), additional services supported (drug discovery, protein-protein interaction analysis and protein expression), type of protein engineering approach used (rational designing, directed evolution and semi-rational designing), type of protein (proteins / peptides, antibodies, enzymes, cytokines and viruses) and type of application (therapeutics and diagnostics).
  • An insightful 2×2 matrix representation of the competitiveness analysis of various protein design and engineering technologies segregated into two peer groups based on the company size of their respective technology provider, namely small (1-50 employees) and mid-sized companies (51-500 employees). Within the peer group, technologies were ranked based on various relevant parameters, such as supplier power (based on the experience of the technology provider) and technology competitiveness (based on parameters, including number of protein design and engineering services supported, number of additional services supported, type of protein and type of application).
  • Elaborate profiles of key players that are engaged in offering technologies for protein design and engineering. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on technology offered, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2017-2021, covering R&D agreements, technology licensing agreements, product development and commercialization agreements, research agreements, service alliances, product development agreements, acquisitions / mergers, technology / software development agreements and other related agreements.
  • An in-depth analysis of over 130 protein / peptide based therapy developers that are likely to partner with protein design and engineering services and technology providers, based on several relevant parameters, such as developer strength (based on company size and its experience), pipeline strength (based on the number of drugs in pipeline and their stage of development and therapeutic area).
  • An in-depth analysis of over 550 patents filed / granted related to protein design and engineering, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, application year, publication year, regional applicability, CPC symbols, emerging focus areas, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.
  • A detailed analysis of completed, ongoing and planned clinical studies of various protein / peptide based therapies on relevant parameters, such as trial registration year, trial phase, trial recruitment status, type of sponsor, target patient segment, leading industry and non-industry players (in terms of number of registered trials conducted) and key geographical regions.
  • A case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.


One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for protein design and engineering market over the coming decade. Additionally, it features market size projections for the protein design and engineering services market, wherein both the current and upcoming opportunity is segmented across [A] type of protein engineering approach used (rational designing, directed evolution and semi - rational designing), [B] type of protein (antibodies, peptides, enzymes, vaccines and others), [C] type of application (therapeutics and diagnostics), [D] type of end user (pharma / biotech firms, CROs and research / academic institutes) and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.


The report features detailed transcripts of interviews held with the following individuals:


  • Roman Badik (Chief Executive Officer, Enantis)
  • Haibin Chen (Vice President, Enzymaster)
  • Naveen Kulkarni (Chief Executive Officer, Quantumzyme)

Key Questions Answered


  • Who are the leading players engaged in providing protein design and engineering services?  
  • What is the relative competitiveness of different protein design and engineering service providers?

  • What are the popular types of protein design and engineering technologies available in the market?

  • What types of partnership models are commonly being adopted by stakeholders in this industry? 

  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?

  • Which are the most active clinical trial centers?

  • What are the major market trends and driving factors that are likely to impact the growth of protein design and engineering market?

  • How is the current and future market opportunity likely to be distributed across key market segments?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Protein Design and Engineering
3.3. Protein Design and Engineering Process
3.3.1. Protein Sequencing
3.3.2. Protein Library Generation
3.3.3. Protein Screening
3.3.4. Protein Expression
3.3.5. Protein Characterization
3.3.6. Protein Quantification
3.3.7. Protein Purification
3.3.8. In-Silico Analysis
3.4. Methods Used for Protein Design and Engineering
3.4.1 Rational Method
3.4.2 Irrational Method / Directed Evolution Method
3.4.3. De-Novo Protein Design Method
3.4.4. Semi-Rational Method / Combinatorial Method
3.5. Applications of Protein Design and Engineering in Pharmaceutical Industry
3.5.1. Disease Diagnosis
3.5.2. Drug Discovery
3.5.3. Development of Protein based Therapeutics
3.5.4. Enzyme Engineering
3.5.5. Antibody Engineering
3.5.6. Virus Engineering
3.6. Challenges Associated with Protein Design and Engineering
3.7. Concluding Remarks
4. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Protein Design and Engineering Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Protein Design and Engineering Service(s) Offered
4.2.5. Analysis by Additional Services Offered
4.2.6. Analysis by Type of Protein Engineering Approach Used
4.2.7. Analysis by Type of Protein
4.2.8. Analysis by Type of Application
4.2.9. Analysis by Type of Protein Expression
5. PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Protein Design and Engineering Services: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Service Providers
5.4.2. Company Competitiveness Analysis: Mid-Sized Service Providers
5.4.3. Company Competitiveness Analysis: Large Service Providers
6. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. ATUM
6.2.1. Company Overview
6.2.2. Protein Design and Engineering Service Offerings
6.2.3. Protein Design and Engineering Technologies
6.2.4. Recent Developments and Future Outlook
6.3. Creative BioMart
6.3.1. Company Overview
6.3.2. Protein Design and Engineering Service Offerings
6.3.3. Recent Developments and Future Outlook
6.4. Creative Biostructure
6.4.1. Company Overview
6.4.2. Protein Design and Engineering Service Offerings
6.4.3. Recent Developments and Future Outlook
6.5. Creative Enzymes
6.5.1. Company Overview
6.5.2. Protein Design and Engineering Service Offerings
6.5.3. Recent Developments and Future Outlook
7. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN EUROPE
7.1. Chapter Overview
7.1. Absolute Antibody
7.1.1. Company Overview
7.1.2. Protein Design and Engineering Service Offerings
7.1.3. Recent Developments and Future Outlook
7.2. EUCODIS Bioscience
7.2.1. Company Overview
7.2.2. Protein Design and Engineering Service Offerings
7.2.3. Protein Design and Engineering Technologies
7.2.4. Recent Developments and Future Outlook
7.3. Fusion Antibodies
7.3.1. Company Overview
7.3.2. Protein Design and Engineering Service Offerings
7.3.3. Protein Design and Engineering Technologies
7.3.4. Financial Information
7.3.5. Recent Developments and Future Outlook
7.4. Innovagen
7.4.1. Company Overview
7.4.2. Protein Design and Engineering Service Offerings
7.4.3. Recent Developments and Future Outlook
7.5. ZYMVOL
7.5.1. Company Overview
7.5.2. Protein Design and Engineering Service Offerings
7.5.3. Protein Design and Engineering Technologies
7.5.4. Recent Developments and Future Outlook
8. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. Averring Biotech
8.2.1. Company Overview
8.2.2. Protein Design and Engineering Service Offerings
8.2.3. Recent Developments and Future Outlook
8.3. EnzymeWorks
8.3.1. Company Overview
8.3.2. Protein Design and Engineering Service Offerings
8.3.3. Recent Developments and Future Outlook
8.4. GeNext Genomics
8.4.1. Company Overview
8.4.2. Protein Design and Engineering Service Offerings
8.4.3. Recent Developments and Future Outlook
8.5. Quantumzyme
8.5.1. Company Overview
8.5.2. Protein Design and Engineering Service Offerings
8.5.3. Protein Design and Engineering Technologies
8.5.4. Recent Developments and Future Outlook
9. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
9.1. Chapter Overview
9.2. Protein Design and Engineering Technology Providers: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Protein Design and Engineering Service(s) Supported
9.2.5. Analysis by Additional Services Supported
9.2.6. Analysis by Type of Protein Engineering Approach Used
9.2.7. Analysis by Type of Protein
9.2.8. Analysis by Type of Application
10. PROTEIN DESIGN AND ENGINEERING TECHNOLOGIES: COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Protein Design and Engineering Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Small Technology Providers
10.4.2. Technology Competitiveness Analysis: Mid-sized Technology Providers
11. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
11.1. Chapter Overview
11.2. Arzeda
11.2.1. Company Overview
11.2.2. Protein Design and Engineering Technologies
11.2.3. Recent Developments and Future Outlook
11.3. Cyrus Biotechnology
11.3.1. Company Overview
11.3.2. Protein Design and Engineering Technologies
11.3.3. Recent Developments and Future Outlook
11.4. Enzymaster
11.4.1. Company Overview
11.4.2. Protein Design and Engineering Technologies
11.4.3. Recent Developments and Future Outlook
11.5. Innovative Targeting Solutions
11.5.1. Company Overview
11.5.2. Protein Design and Engineering Technologies
11.5.3. Recent Developments and Future Outlook
11.6. Proteus
11.6.1. Company Overview
11.6.2. Protein Design and Engineering Technologies
11.6.3. Recent Developments and Future Outlook
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Protein Design and Engineering Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Focus Area
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Geographical Analysis
12.3.6.1. Region-wise Distribution
12.3.6.2. Country-wise Distribution
13. LIKELY PARTNERS ANALYSIS
13.1. Chapter Overview
13.2. Scoring Criteria and Key Assumptions
13.3. Scope and Methodology
13.4. Potential Strategic Partners
13.4.1. Potential Strategic Partners in North America
13.4.1.1. Most Likely Partners in North America
13.4.1.2. Likely Partners in North America
13.4.1.3. Less Likely Partners in North America
13.4.2. Potential Strategic Partners in Europe
13.4.2.1. Most Likely Partners in Europe
13.4.2.2. Likely Partners in Europe
13.4.2.3. Less Likely Partners in Europe
13.4.3. Potential Strategic Partners in Asia Pacific
13.4.3.1. Most Likely Partners in Asia Pacific
13.4.3.2. Likely Partners in Asia Pacific
13.4.3.3. Less Likely Partners in Asia Pacific
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Protein Design and Engineering Market: Patent Analysis
14.3.1. Analysis by Application Year
14.3.2. Analysis by Publication Year
14.3.3. Analysis by Geography
14.3.4. Analysis by CPC Symbols
14.3.5. Emerging Focus Areas
14.3.6. Analysis by Type of Organization
14.3.7. Leading Players: Analysis by Number of Patents
14.4. Protein Design and Engineering Market: Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics
14.5. Protein Design and Engineering Market: Patent Valuation Analysis
14.6. Leading Patents by Number of Citations
15. CLINICAL TRIAL ANALYSIS
15.1. Chapter overview
15.2. Scope and Methodology
15.3. Protein / Peptide Therapeutics: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
15.3.3. Analysis by Trial Phase
15.3.4. Analysis by Recruitment Status
15.3.5. Analysis by Type of Sponsor / Collaborator
15.3.6. Analysis by Target Patient Segment
15.3.7. Leading Industry Players: Analysis by Number of Registered Trials
15.3.8. Leading Non-Industry Players: Analysis by Number of Registered Trials
15.3.9. Analysis of Clinical Trials by Geography
15.3.10. Analysis of Enrolled Patient Population by Geography
16. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
16.1. Chapter Overview
16.2. Overview of Novel Peptide Therapeutics
16.3. Advantages and Applications of Novel Peptide Therapeutics
16.4. Key Challenges Associated with Novel Peptide Therapeutics
17. MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Global Protein Design and Engineering Services Market, 2021-2035
17.4. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used
17.5. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein
17.6. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application
17.7. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User
17.8. Protein Design and Engineering Services Market, 2021-2035: Distribution by Region
17.8.1. Protein Design and Engineering Services Market in North America, 2021-2035
17.8.2. Protein Design and Engineering Services Market in Europe, 2021-2035
17.8.3. Protein Design and Engineering Services Market in Asia Pacific, 2021-2035
17.8.4. Protein Design and Engineering Services Market in Latin America, 2021-2035
17.8.5. Protein Design and Engineering Services Market in MENA, 2021-2035
17.8.6. Protein Design and Engineering Services Market in Rest of the World, 2021-2035
18. CONCLUDING REMARKS
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Enantis
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Roman Badik, Chief Executive Officer
19.3. Enzymaster
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Haibin Chen, Vice President
19.4. Quantumzyme
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Naveen Kulkarni, Chief Executive Officer
20. APPENDIX 1: TABULATED DATA21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 13therapeutics
  • 9 Meters Biopharma
  • Ablynx
  • Absolute Antibody
  • Abzena
  • Accelero Biostructures 
  • Advanced Accelerator Applications
  • AffyPro
  • Aileron Therapeutics
  • Akashi Therapeutics
  • Allozymes
  • Allysta Pharmaceuticals
  • Altimmune
  • Ambrx
  • Amgen
  • Aminoverse
  • Amolyt Pharma
  • Ampio Pharmaceuticals
  • Amyndas Pharmaceuticals
  • Anji Pharmaceuticals
  • Apellis Pharmaceuticals
  • Apeptico
  • APIM Therapeutics
  • Apitope
  • Aquestive Therapeutics
  • Arch Biopartners
  • Arzeda
  • AsclepiX Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Atox Bio
  • Atreca
  • ATUM
  • August Bioservices
  • Aurinia Pharmaceuticals
  • Averin Biotech
  • Avilex Pharma
  • Bayer
  • Bicycle Therapeutics
  • BioLineRx
  • Biolingus
  • Biologics International
  • Biomarck Pharmaceuticals
  • BioMarin Pharmaceutical
  • BioMetis Technology
  • BioTickle
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Bristol Myers Squibb
  • Broad Institute of MIT and Harvard
  • California Institute of Technology
  • CanBas
  • Cancer Research UK
  • candidum
  • Cara Therapeutics
  • Carmot Therapeutics
  • Cellivery Therapeutics
  • Cend Therapeutics
  • ChemPartner
  • Chiasma Pharma
  • China Agricultural University
  • Chondropeptix
  • ChromoTek
  • Chrysalis BioTherapeutics
  • Clinuvel Pharmaceuticals
  • Codex DNA
  • Codexis
  • CohBar
  • Columbia University
  • Constant Therapeutics
  • Creative Biolabs
  • Creative BioMart
  • Creative Biostructure
  • Creative Enzymes
  • CureDM
  • Curonz
  • Cyrus Biotechnology
  • Cytovation
  • Cytovia Therapeutics
  • Dana-Farber Cancer Institute
  • Dezyme
  • Diabetology
  • Diapin Therapeutics
  • DNASTAR
  • Early Drug Development Group (E2DG)
  • Eli Lilly
  • Emory University
  • Enantis 
  • Entera Bio
  • Enteris BioPharma
  • Enzymaster
  • EnzymeWorks
  • Esperance Pharmaceuticals
  • EUCODIS Bioscience 
  • EUPROTEIN 
  • Eurofins
  • EvoEnzyme
  • Evozyne
  • exonbio 
  • F4 Pharma
  • Factor Bioscience
  • Ferring Pharmaceuticals
  • FinsnoBio
  • Frontier Korea
  • Fujitsu 
  • FirstString Research
  • Follicum
  • Fornia BioSolutions
  • Frontier Biotechnologies
  • Fusion Antibodies
  • Genentech
  • Genervon Biopharmaceuticals
  • GeNext Genomics
  • Genomica
  • GenScript
  • Genus Oncology
  • Gila Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline
  • GlioCure
  • Harvard University 
  • HELIOPOLIS BIOTECH
  • HighTide Therapeutics
  • iBio
  • ILC Therapeutics
  • Imcyse
  • ImmuPharma
  • Innovagen AB
  • Innovative Targeting Solutions
  • Inotrem
  • Inscripta
  • Integral Molecular
  • InterK Peptide Therapeutics
  • Issar Pharmaceuticals
  • iXpressGenes
  • Janssen Biotech
  • Kalos Therapeutics
  • Kerafast
  • La Jolla Pharmaceutical
  • LabGenius 
  • Laboratory of Computational Biology 
  • LakePharma (acquired by Curia)
  • Lassogen
  • Lead Discovery Siena
  • Leland Stanford Junior University
  • Longevity Biotech
  • LifeSpan BioSciences (LSBio)
  • Macromoltek
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Mayo Clinic
  • MD Anderson Cancer Center
  • MedImmune
  • MElkin Pharmaceuticals
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • MeSCue-Janusys
  • Mid-Atlantic BioTherapeutics (MABT)
  • Millennium Pharmaceuticals
  • Molecular Loop
  • Molecular Partners
  • Mologic
  • Molsoft
  • Nanomerics
  • National Cancer Institute (NCI)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Nestlé Health Science
  • Neurozon
  • Next Interactions
  • NextPharma
  • NoNO
  • Nostrum Biodiscovery
  • NovaCell Technology
  • Novartis
  • Novo Nordisk
  • NVIDIA
  • NYU Langone Health
  • Oak BioSciences
  • Olympic Protein Technologies (OPT) 
  • ONL Therapeutics
  • OpenEye Scientific
  • OPKO Health
  • Oramed Pharmaceuticals
  • OriMAbs
  • Ovoca Bio
  • Oxalo Therapeutics
  • Oxurion
  • Palatin Technologies
  • PEACCEL 
  • PEP-Therapy
  • PeptiDream
  • Peptilogics
  • Peptone 
  • Peptron
  • PharmaMar
  • Pieris Pharmaceuticals
  • PIN Pharma
  • Plabeltech
  • Polyclone Bioservices
  • Polyphor
  • Porton Pharma Solutions
  • Priavoid
  • ProLynx
  • ProMab Biotechnologies
  • ProMore Pharma
  • ProNeurogen
  • Protagonist Therapeutics
  • Protein Alternatives SL (PROALT)
  • Protein Design
  • ProteinQure
  • Proteus by Seqens
  • Pulmotect
  • Quantum Hi-Tech (China) Biological
  • Quantumzyme
  • Queen’s University Belfast
  • Radius Health
  • Rani Therapeutics
  • Ranomics
  • RD-BIOTECH
  • Regeneron Pharmaceuticals
  • RegeneRx Biopharmaceuticals
  • ReGenTree
  • Revolve Biotechnologies
  • Rhythm Pharmaceuticals
  • Roche
  • Safic-Alcan
  • Salix Pharmaceuticals
  • Sanofi
  • Santhera Pharmaceuticals
  • Sapience Therapeutics
  • Scotia Biologics
  • Scotia Biologics
  • Seachaid Pharmaceuticals
  • Selecta Biosciences
  • Sentebiolab
  • Serpin Pharma
  • SeSaM-Biotech
  • Soligenix
  • Soricimed Biopharma
  • Stealth BioTherapeutics
  • Structure Based Design (SBD)
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (SOBI)
  • Synbio Technologies
  • Synbuild
  • SYNG Pharmaceuticals
  • Synthorx (acquired by Sanofi)
  • Takeda Pharmaceuticals
  • Tarsa Therapeutics
  • TC BioPharm
  • TCR2 Therapeutics
  • TearSolutions
  • Technical University of Denmark
  • TeselaGen Biotechnology
  • The University of Texas
  • TheraSource
  • Thermo Fisher Scientific
  • Topas Therapeutics
  • Twist Bioscience
  • TwoToBiotech
  • University of California, San Francisco (UCSF)
  • UCB Pharma
  • UCLA Technology Development Group
  • University of California
  • University of Chicago
  • University of Toronto
  • University of Washington
  • Vault Pharma
  • Vaxeal
  • Verne Global
  • Viatem
  • Vir Biotechnology
  • Watchmaker Genomics
  • Xen Biofluidx
  • Xencor
  • Xigen
  • XPose Therapeutics
  • YUMAB
  • Zealand Pharma
  • Zucara Therapeutics
  • Zummit Infolabs
  • Zymeworks
  • Zymvol Biomodeling

Methodology

 

 

Loading
LOADING...